Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.
作者： Lisha Wang , Fei Ren , Qifeng Wang , Lee Ann Baldridge , M. Francesca Monn
DOI: 10.1007/S40291-016-0188-1
关键词: Survival analysis 、 Molecular medicine 、 Medicine 、 Internal medicine 、 Oncology 、 Immune system 、 Colorectal cancer 、 Immune checkpoint 、 Univariate analysis 、 PD-L1 、 Immunotherapy
摘要: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis patients with colorectal cancer remains to be determined. We assessed levels PD-L1 tumor-infiltrating immune cells as well tumor cells, and evaluated association between clinical outcome 262 patients. In univariate analysis, TNM stage (p < 0.001), (p = 0.016), location (p = 0.033), size (p = 0.019) were associated survival. multivariate infiltrating independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 1.51–4.12, p < 0.001, respectively). Eight percent had positive cells. contrast, was not significantly patient outcome. Our data indicate that status is a significant factor There need for randomized studies evaluate role treatment decision protocols novel immunotherapy.
springer.com
sci-hub.se 参考文章(42)
Fred T Bosman, Fatima Carneiro, Ralph H Hruban, Neil D Theise, WHO Classification of Tumours of the Digestive System WHO classification of tumours of the digestive system.. ,(2010)
F. Bosman, Comprar WHO Classification of Tumours of the Digestive System | F. Bosman | 9789283224327 | WHO World Health Organization WHO World Health Organization. ,(2010)
Shin Foong Ngiow, Arabella Young, Nicolas Jacquelot, Takahiro Yamazaki, David Enot, Laurence Zitvogel, Mark J. Smyth, A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1 Cancer Research. ,vol. 75, pp. 3800- 3811 ,(2015) , 10.1158/0008-5472.CAN-15-1082
C D Fankhauser, A Curioni-Fontecedro, V Allmann, J Beyer, V Tischler, T Sulser, H Moch, P K Bode, Frequent PD-L1 expression in testicular germ cell tumors British Journal of Cancer. ,vol. 113, pp. 411- 413 ,(2015) , 10.1038/BJC.2015.244
Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman, Combination cancer immunotherapy and new immunomodulatory targets Nature Reviews Drug Discovery. ,vol. 14, pp. 561- 584 ,(2015) , 10.1038/NRD4591
Kurt W Fisher, Antonio Lopez-Beltran, Rodolfo Montironi, Liang Cheng, Precision medicine in colorectal cancer: Evolving genomic landscape and emerging consensus Future Oncology. ,vol. 11, pp. 2711- 2719 ,(2015) , 10.2217/FON.15.219
Thomas Powles, Joseph Paul Eder, Gregg D. Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature. ,vol. 515, pp. 558- 562 ,(2014) , 10.1038/NATURE13904
Nicolas J Llosa, Michael Cruise, Ada Tam, Elizabeth C Wicks, Elizabeth M Hechenbleikner, Janis M Taube, Richard L Blosser, Hongni Fan, Hao Wang, Brandon S Luber, Ming Zhang, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Cynthia L Sears, Robert A Anders, Drew M Pardoll, Franck Housseau, None, The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints Cancer Discovery. ,vol. 5, pp. 43- 51 ,(2015) , 10.1158/2159-8290.CD-14-0863
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian, Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Journal of Clinical Oncology. ,vol. 28, pp. 3167- 3175 ,(2010) , 10.1200/JCO.2009.26.7609